Overview
Synergies Within the MS Care Team: Optimizing Outcomes and Increasing Patient Adherence with Initial Therapies
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This web-based clinical roundtable endeavors to provide MS healthcare team members with strategies to use their specialized skill sets collaboratively in order to improve patient outcomes in MS.
The activity will educate members of the MS healthcare team on the following 3 themes: 1) the need to optimize first-line DMT therapies; 2) strategies that can be employed by each caregiver to minimize adverse events and increase patient medication adherence and 3) approaches that can be utilized by the comprehensive care team to ensure seamless patient transitions, thereby improving patient outcomes.
The Clinical Commentary will help to individualize care by providing clinicians with current data to aid them in providing the best possible care to their patients with relapsing and remitting multiple sclerosis.
The activity will educate members of the MS healthcare team on the following 3 themes: 1) the need to optimize first-line DMT therapies; 2) strategies that can be employed by each caregiver to minimize adverse events and increase patient medication adherence and 3) approaches that can be utilized by the comprehensive care team to ensure seamless patient transitions, thereby improving patient outcomes.
The Clinical Commentary will help to individualize care by providing clinicians with current data to aid them in providing the best possible care to their patients with relapsing and remitting multiple sclerosis.
This educational activity is designed for neurologists, MS specialists, specialty pharmacists, MS nurses, and other clinicians involved in the management of patients with relapsing and remitting multiple sclerosis (RRMS).
Upon completion of this activity, participants will be able to:
• Review position statements outlined in the MS Coalition 2014 Consensus Update with regard to the initiation of DMT use in newly diagnosed patients and the management of adverse events.
• Employ strategies tailored by the healthcare team and for use with the patient that can be used to minimize adverse events associated with DMTs.
• Illustrate how technologies and coordinated care can be used in concert to help improve patient medication adherence and quality of life.
This activity is supported by an educational grant from Teva Pharmaceuticals.
To participate in this activity, you must have an active internet connection, 256 MB of RAM or higher. This activity is best viewed using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, and Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required. Adobe Reader® is required to print certificates.
If you have questions about this topic and would like to ask Dr. Kreiger, Ms. Perrin-Ross, or Mr. Soni a question, click on "Ask the Expert" on the top of this page. Responses and new information will be shared in the Discussion Board, and as the submitter, you will also receive a direct response to your inquiry.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Stephen Krieger, MD
Associate Professor of Neurology
Corinne Goldsmith Dickinson Center for MS
Mount Sinai
New York, NY
Associate Professor of Neurology
Corinne Goldsmith Dickinson Center for MS
Mount Sinai
New York, NY
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Neuroscience Program Coordinator
Loyola University Medical Center/MS Center
Maywood, IL
Dhruv Soni, PharmD
Senior Pharmacist
Brigham and Women’s Hospital
Boston, MA
Marlene Hilton
Professional Moderator
ACHL requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
Stephen Krieger, MD
Amy Perrin Ross, APN, MSN, CNRN, MSCN
The following financial relationships have been provided:
Marlene Hilton and Dhruv Soni, PharmD
No relevant affiliations or financial relationships to disclose.
Stephen Krieger, MD
Consultant: Acorda Therapeutics, Bayer HealthCare Pharmaceuticals, Biogen Idec, EMD Serono, Inc, Genentech, Genzyme Corporation, Mallinckrodt Pharmaceuticals, Novartis Pharmaceuticals Corporation, Takeda Pharmaceuticals North America, Inc, Teva Pharmaceuticals
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Advisor, Consultant, Speakers Bureau: Acorda Therapeutics, Bayer HealthCare Pharmaceuticals, Biogen Idec, EMD Serono, Inc, Genzyme Corporation, Mallinckrodt Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer, Inc, Teva Pharmaceuticals
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pre-test, view the online activity and complete the post-test and evaluation. To receive credit, 80% must be achieved on the post-test. A certificate will be immediately available. A statement of participation will be immediately available for pharmacists and pharmacist credit will be uploaded to CPE Monitor within 60 days of completion. There is no fee to participate in the activity or for the generation of the certificate.
Physicians:
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses:
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses:
Provider approved by the California Board of Registered Nursing, Provider Number 14803 for 1 contact hour.
Pharmacists:
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 1.0 contact hour.
ACPE Universal Activity Number: 0396-0000-15-044-H04-P
Activity Type(s): Application
Release Date: 11/16/15
Expiration Date: 11/16/16
